"Based on the numbers reported to the agency so far" The key word is "so far", the article explains that Germany saw the number double since the reporting. ht

"Based on the numbers reported to the agency so far" The key word is "so far", the article explains that Germany saw the number double since the reporting. https://www.ft.com/content/d5cd63c6-af01-4d29-a5e5-b69ade4f3803 https://www.ft.com/content/d5cd63c6-af01-4d29-a5e5-b69ade4f3... Reports it as 10x the normal occurence of 3 per 100k. (and I assume that's before doing further slicing, probably slicing for younger women would show even more impact?). I'm all for vaccine but it's a tight rope to have a successful rollout in EU: https://www.theatlantic.com/health/archive/2021/03/astrazeneca-vaccine-blood-clot-issue-wont-go-away/618451/ https://www.theatlantic.com/health/archive/2021/03/astrazene... Maybe they could consider reserving the non-AZ doses to the most likely to be affected demographic. (personally I'm lucky enough to be in a country that's not planning on using the AZ vaccine so there's no question, but rest of EU is different)